SCHEMBL1285630

SCHEMBL1285630

Cc1cc(Nc2cc(Cl)ncn2)cc2oc(=O)n(C)c12

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 1/20 0.40
▸ MKNK1 Q9BUB5 1/20 0.37
▸ MAPK14 Q16539 1/20 0.36
▸ GABRG2 P18507 1/20 0.34
▸ GABRB3 P28472 1/20 0.34
▸ GABRA5 P31644 1/20 0.34
▸ ACACB O00763 1/20 0.33
▸ WDR5 P61964 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ PKM P14618 2/20 0.32
▸ KDM4E B2RXH2 1/20 0.32
▸ TNNI3K Q59H18 1/20 0.31
▸ JAK1 P23458 2/20 0.31
▸ JAK3 P52333 2/20 0.31
▸ EGFR P00533 1/20 0.30
▸ HTR3A P46098 1/20 0.30
▸ CCNT1 O60563 1/20 0.30
▸ CDK9 P50750 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1285338 0.75 SYK (0.48) NPC1MKNK1MAPK14JAK1JAK3
SCHEMBL1285874 0.70 NPC1 (0.53) NPC1MKNK1MAPK14KMT2AEGFR
SCHEMBL16435008 0.70 ACACB (0.43) NPC1ACACBKMT2APKMKDM4E
SCHEMBL3659884 0.68 ALDH1A1 (0.43) MAPK14ACACBKDM4E
SCHEMBL1285331 0.68 NPC1 (0.44) NPC1MKNK1MAPK14GABRG2GABRB3
SCHEMBL1285052 0.67 NPC1 (0.55) NPC1MKNK1KMT2AEGFR
SCHEMBL12787337 0.67 ACACB (0.41) ACACBKMT2APKMKDM4E
SCHEMBL1701298 0.66 ACACB (0.36) ACACBKMT2APKMKDM4E
SCHEMBL3659336 0.66 ALDH1A1 (0.35) ACACB
SCHEMBL3658099 0.65 ALDH1A1 (0.41) ACACBKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2379529-B1 CGRP-ANTAGONISTS BOEHRINGER INGELHEIM INT (DE) 2015-06-10 — — EP disclosed
EP-2379529-B1 CGRP-ANTAGONISTS BOEHRINGER INGELHEIM INT (DE) 2015-06-10 — — EP disclosed
US-8952014-B2 Pyrimidine derivatives which are CGRP—antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-02-10 — — US disclosed
US-8952014-B2 Pyrimidine derivatives which are CGRP—antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-02-10 — — US disclosed
US-8952014-B2 Pyrimidine derivatives which are CGRP—antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-02-10 — — US disclosed
US-20120088755-A1 Novel Compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-04-12 — — US disclosed
US-20120088755-A1 Novel Compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-04-12 — — US disclosed
US-20120088755-A1 Novel Compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-04-12 — — US disclosed
EP-2379529-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-10-26 — — EP disclosed
WO-2010070022-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-06-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088755-A1 Novel Compounds SLC26A4, F12, SLCO1B3 NPC1 1283/4885MKNK1 4735/4885MAPK14 4476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback